Last Updated: November 16, 2026

List of Excipients in Branded Drug COTELLIC

« Back to Dashboard


Company Tradename Ingredient NDC Excipient Potential Generic Entry
Genentech Inc COTELLIC cobimetinib 50242-717 CELLULOSE, MICROCRYSTALLINE 2030-05-10
Genentech Inc COTELLIC cobimetinib 50242-717 CROSCARMELLOSE SODIUM 2030-05-10
Genentech Inc COTELLIC cobimetinib 50242-717 LACTOSE MONOHYDRATE 2030-05-10
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Cotellic (Cobimetinib) Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Cotellic is a once-daily oral cobimetinib tablet used with vemurafenib for adults with unresectable or metastatic melanoma carrying a BRAF V600E or V600K mutation. The marketed product is a 20 mg immediate-release film-coated tablet. Its relatively simple excipient system creates opportunities for generic development, regional supply, excipient substitution, and differentiated oral formulations, but the commercial ceiling is constrained by combination therapy, targeted safety monitoring, competing BRAF/MEK regimens, and the absence of biologic-style barriers to generic entry.

The highest-value opportunities are likely to be:

  1. A bioequivalent 20 mg immediate-release tablet with a robust, low-cost direct-compression process.
  2. A formulation with improved stability, lower tablet weight, or reduced lactose exposure.
  3. A combination or co-pack strategy involving cobimetinib and vemurafenib.
  4. Regional licensing for generic or authorized-generic supply after applicable patent and regulatory barriers expire.
  5. Reformulations that improve adherence or support dose flexibility without creating unnecessary clinical or regulatory requirements.

What is Cotellic and how is it administered?

Cotellic contains cobimetinib fumarate, a small-molecule MEK1/2 inhibitor. The approved regimen is 60 mg orally once daily for 21 consecutive days followed by a seven-day break in each 28-day cycle. Cotellic is administered with vemurafenib, a BRAF inhibitor, in patients whose tumors have BRAF V600E or V600K mutations confirmed by an FDA-approved test (FDA, 2024a).

Attribute Cotellic
Active ingredient Cobimetinib fumarate
Brand owner Genentech, a Roche company
Dosage form Immediate-release film-coated tablet
Strength 20 mg
Dose 60 mg once daily for 21 days, then seven days off
Primary use BRAF V600E or V600K unresectable or metastatic melanoma
Combination partner Vemurafenib
Route Oral
FDA approval 2015
Product category Small-molecule oncology drug
Biosimilar pathway Not applicable
Generic pathway Abbreviated New Drug Application, subject to applicable patent and exclusivity barriers

Cotellic is also exposed to treatment interruptions and dose reductions because of rash, diarrhea, photosensitivity, cardiomyopathy, ocular toxicity, hepatotoxicity, and creatine phosphokinase elevation. A formulation that supports reliable dosing at lower strengths could have clinical utility, although the commercial value would depend on whether the FDA considers the product therapeutically equivalent or requires additional evidence.

What excipients are used in Cotellic tablets?

The U.S. prescribing information identifies a conventional tablet core and film-coating system. The inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, and iron oxide-based colorant components, according to the product labeling (FDA, 2024a).

Formulation function Cotellic excipient or excipient class Commercial role
Diluent Lactose monohydrate Adds bulk and supports tablet compression
Diluent and compression aid Microcrystalline cellulose Improves compactability and tablet strength
Superdisintegrant Croscarmellose sodium Promotes tablet breakup and dissolution
Lubricant Magnesium stearate Reduces tooling friction and ejection force
Film former Polyvinyl alcohol Provides the coating matrix
Opacifier and pigment Titanium dioxide Supports coating appearance and opacity
Anti-tacking and coating aid Talc Improves coating processing
Colorant Iron oxide Supports product identification

The excipient strategy is therefore conventional rather than highly specialized. No lipid vehicle, amorphous solid dispersion, enteric system, osmotic device, or modified-release polymer is identified in the U.S. label. That structure lowers manufacturing complexity and reduces the likelihood that a generic applicant would need to replicate a technically unusual delivery system.

How does Cotellic’s excipient system affect generic development?

The core formulation is compatible with standard wet granulation or direct-compression development, depending on the physical properties of the cobimetinib drug substance and selected salt form. The commercial target is a tablet that matches the reference product in dissolution, dose uniformity, mechanical strength, stability, and appearance.

Key development risks include:

  • Low-dose uniformity if the active is present at a relatively low percentage of total tablet mass.
  • Lubricant sensitivity, particularly over-lubrication with magnesium stearate.
  • Dissolution variation caused by particle-size distribution, polymorphism, or drug-excipient interactions.
  • Coating weight variation and color matching.
  • Lactose compatibility if the active or process introduces moisture or reactive impurities.
  • Stability changes caused by alternate grades of microcrystalline cellulose or croscarmellose sodium.

A generic manufacturer does not usually need to copy every excipient quantitatively. The formulation must meet applicable FDA quality and bioequivalence standards, and inactive ingredients must be acceptable for the route and dosage form. A substitute formulation using mannitol, dibasic calcium phosphate, starch-based disintegrants, or a different film-coating system could be commercially viable if it performs equivalently.

What excipient substitutions offer the strongest commercial opportunity?

Lactose-free Cotellic tablets

Replacing lactose with mannitol, anhydrous dibasic calcium phosphate, or a suitable cellulose-based diluent could create a lactose-free product. The commercial opportunity is limited because lactose intolerance is generally not a major barrier at the small excipient quantities used in tablets. The value would be greater in markets where lactose-free labeling supports hospital formulary or procurement preferences.

Lower-weight direct-compression tablets

A higher-functionality excipient platform could reduce tablet mass and simplify manufacturing. Co-processed microcrystalline cellulose systems, spray-dried mannitol, and silicified cellulose can improve flow and compactability. This approach may reduce production cost and packaging volume, but it must preserve content uniformity for a potent oncology active.

Improved disintegration and dissolution

Croscarmellose sodium is already a standard superdisintegrant. Alternatives such as crospovidone or sodium starch glycolate could be tested where they provide faster or more consistent dissolution. This is most commercially relevant if cobimetinib shows dissolution sensitivity to particle size, salt form, or storage conditions.

Titanium-dioxide-free coating

Titanium dioxide restrictions and customer preferences have encouraged alternative coating systems using calcium carbonate, starch, or other approved pigments. A titanium-dioxide-free tablet could simplify supply in selected jurisdictions. The opportunity is regulatory and procurement-driven rather than clinical.

Moisture-control formulations

A moisture-protective coating, high-barrier blister, or desiccant-containing package may improve shelf life in hot and humid markets. Packaging can be more commercially efficient than changing the core excipients, particularly if the reference product already has adequate dissolution and bioavailability.

What formulation patents may protect Cotellic or generic alternatives?

Cotellic’s principal commercial protection is expected to arise from active-ingredient, pharmaceutical-composition, manufacturing, and method-of-use patents rather than from the publicly disclosed tablet excipient system alone. The label does not establish that the specific excipient combination is independently protected.

Potential patent categories include:

Patent category Relevance to Cotellic
Cobimetinib composition-of-matter patents Protect the active molecule or defined chemical forms
Salt and polymorph patents May cover cobimetinib fumarate or solid-state forms
Pharmaceutical-composition patents May cover particular dosage forms or excipient combinations
Manufacturing patents May cover synthesis, crystallization, purification, or particle engineering
Method-of-use patents May cover BRAF-mutant melanoma or combination treatment
Combination patents May cover cobimetinib with vemurafenib or other anticancer agents
Formulation patents Could cover dissolution enhancement, stability, or modified delivery

A generic excipient substitution does not avoid a composition-of-matter patent. It may, however, reduce exposure to a narrowly drafted formulation claim if the substitute product uses different excipients, different manufacturing parameters, or a different solid form. A freedom-to-operate analysis must review issued claims, terminal disclaimers, patent-term adjustments, Orange Book listings, and the applicant’s proposed labeling.

What is the FDA regulatory status and Orange Book position for Cotellic?

Cotellic was approved by the FDA in November 2015 for use with vemurafenib in BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma (FDA, 2015). It is a small-molecule drug and is therefore subject to the ANDA framework rather than the biosimilar pathway.

The regulatory questions for a generic applicant are:

  1. Whether a reference listed drug remains eligible for ANDA referencing.
  2. Which patents are listed in the FDA Orange Book.
  3. Whether those patents have expired, been delisted, or remain subject to a Paragraph IV certification.
  4. Whether pediatric exclusivity or other regulatory exclusivity remains active.
  5. Whether the applicant must challenge method-of-use patents or carve protected indications from its labeling.

Because the public label does not identify the current live patent estate, patent numbers and expiration dates should not be inferred from the brand label. Orange Book status can change through patent-listing updates, delistings, litigation, and statutory patent-term adjustments. A current FDA Orange Book review is required before making a launch or Paragraph IV decision (FDA, 2024b).

When does Cotellic lose exclusivity and when can generic entry occur?

Cotellic received new chemical entity exclusivity after its 2015 approval. The standard five-year NCE period would have expired in 2020, subject to the applicable statutory calculation. That event did not by itself authorize generic launch because listed patents and litigation could extend commercial protection.

A generic entrant may pursue:

  • Paragraph I certification if no relevant patent is listed.
  • Paragraph II certification if a listed patent has expired.
  • Paragraph III certification with a future launch date.
  • Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.
  • A section viii statement to omit a patented method of use from labeling, where legally available.

A Paragraph IV notice can trigger patent litigation and a 30-month stay of ANDA approval under the Hatch-Waxman framework, subject to statutory exceptions. The commercial launch date therefore depends on the patent estate, litigation outcome, settlement terms, and FDA approval timing, not solely on the 2015 approval date.

Which companies are likely to challenge Cotellic?

Cotellic is a plausible target for specialty generic manufacturers with oncology capabilities, particularly companies that already develop kinase inhibitors or high-value oral oncology products. Potential participants in a competitive entry set include Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy’s, Zydus, Aurobindo, Cipla, and regional oncology-generic companies.

No company should be identified as an actual Paragraph IV challenger without a verified ANDA litigation record or court filing. The relevant competitive indicators are:

  • ANDA litigation in the U.S. District Court for the District of Delaware or another jurisdiction.
  • FDA approval of a tentative or final ANDA.
  • Patent-listing activity in the Orange Book.
  • Paragraph IV notices reported in court complaints.
  • Launch announcements in Canada, Europe, India, or other markets.
  • Supply agreements with oncology distributors.

How does Cotellic compare with competing BRAF and MEK therapies?

Cotellic competes primarily with combination regimens rather than with MEK inhibitors used alone.

Regimen Active agents Commercial implication
Cotellic plus Zelboraf Cobimetinib plus vemurafenib Direct Cotellic combination
Braftovi plus Mektovi Encorafenib plus binimetinib Major competing BRAF/MEK regimen
Tafinlar plus Mekinist Dabrafenib plus trametinib Established BRAF/MEK competitor
Mekinist-based combinations Trametinib with selected partners Broader MEK inhibitor competition
Immunotherapy regimens PD-1 or CTLA-4-based therapy Competes for treatment sequencing and market share

Cotellic’s excipient opportunity is stronger in generic supply and procurement than in premium differentiation. A new formulation would need to show a meaningful advantage in stability, administration, adherence, or supply economics to displace a conventional tablet.

What licensing and commercial opportunities exist for Cotellic excipients?

The most realistic licensing models are:

Generic finished-dose licensing

A formulation developer can license a bioequivalent cobimetinib tablet to a regional pharmaceutical company. The deal may include technology transfer, regulatory filing support, and territory-specific supply rights.

Excipient platform licensing

An excipient supplier can license a co-processed diluent, coating system, or moisture-control technology to a generic manufacturer. The value is strongest if the platform improves content uniformity, reduces production steps, or solves a stability problem.

Contract manufacturing

An oncology-focused CDMO can offer drug-product manufacturing, analytical method transfer, packaging, and serialization. Small and mid-sized entrants may prefer an outsourced model because oncology products require specialized containment and high-quality systems.

Combination co-packaging

A co-pack containing cobimetinib and vemurafenib could simplify dispensing and reduce medication errors. The approach would require careful regulatory review because the products may have different labels, dosing instructions, packaging constraints, and safety information.

Regional commercialization

Markets with established oncology generic channels may support licensing of cobimetinib tablets after local patent and regulatory review. The opportunity is more likely to be attractive in countries where Roche’s branded pricing remains high and reimbursement systems favor generic substitution.

What manufacturing and IP barriers affect Cotellic?

The active pharmaceutical ingredient and solid-state form may create greater barriers than the marketed excipients. Manufacturing risks include control of particle size, crystallinity, residual solvents, impurity profile, and batch-to-batch content uniformity. Oncology APIs also require effective operator protection and contamination controls.

The principal IP risks are:

  • Active-ingredient or salt-form patents.
  • Solid-state or polymorph claims.
  • Process patents covering commercially efficient synthesis.
  • Combination patents involving vemurafenib.
  • Method-of-use patents covering BRAF-mutant melanoma.
  • Narrow formulation claims that capture specific dissolution or stability solutions.

An excipient strategy should therefore be designed alongside a patent strategy. Substituting lactose or changing the film coating may have limited value if the same cobimetinib solid form remains within a valid composition-of-matter claim.

How strong is the Cotellic patent estate?

Cotellic’s patent strength cannot be ranked from the label alone. At a high level, composition-of-matter protection is generally more difficult to design around than a narrow excipient claim. Method-of-use patents may be commercially important if they cover the principal labeled indication, but their effect can be reduced through a section viii carve-out where permitted.

For diligence purposes, the estate should be scored across five dimensions:

Factor Strategic weight
Active-ingredient and salt-form claims High
Remaining patent term High
Orange Book listing quality High
Litigation and settlement history High
Formulation-specific claim scope Medium

The commercial conclusion is direct: formulation innovation can reduce development cost and improve supply economics, but it is unlikely to eliminate core patent risk without a verified non-infringing active form and legally supportable labeling strategy.

Key Takeaways

  • Cotellic is a 20 mg immediate-release cobimetinib tablet used with vemurafenib.
  • Its publicly disclosed excipient system is conventional and supports generic formulation work.
  • The main formulation opportunities are lactose replacement, lower tablet weight, improved dissolution control, titanium-dioxide-free coating, and moisture-protective packaging.
  • A generic applicant should prioritize content uniformity, solid-state control, dissolution matching, and stability.
  • Cotellic is subject to the ANDA pathway, not the biosimilar pathway.
  • NCE exclusivity from the 2015 approval is no longer the primary barrier; current patent listings and litigation determine launch risk.
  • The strongest commercial models are generic finished-dose licensing, regional commercialization, CDMO supply, and excipient-platform licensing.
  • Combination therapy, competing BRAF/MEK regimens, and oncology safety monitoring limit the value of premium reformulation.
  • The active ingredient, salt form, solid state, manufacturing process, and method-of-use patents may matter more than the disclosed excipient composition.

FAQs

Can Cotellic be reformulated as a capsule?

Yes, a capsule could be developed, but it would require regulatory justification and bioequivalence work. A capsule would not automatically avoid active-ingredient or method-of-use patents.

Is there a commercial rationale for a Cotellic orally disintegrating tablet?

The rationale is limited. An orally disintegrating tablet could help selected patients with swallowing difficulty, but the oncology market may not support the added development and packaging cost unless it improves adherence or enables a differentiated label.

Would a lactose-free Cotellic generic command a premium?

Usually not by itself. Lactose-free positioning may support procurement or patient-preference advantages, but price competition in generic oncology products would likely dominate.

Can cobimetinib and vemurafenib be sold in a single fixed-dose tablet?

A fixed-dose combination would require substantial formulation, clinical, stability, and regulatory development. Different dosing interruptions and toxicity-management requirements may make a fixed-dose tablet less practical than a co-pack.

Are biosimilars a threat to Cotellic?

No. Cobimetinib is a chemically synthesized small molecule. Competitive follow-on products would generally be generics filed through the ANDA pathway rather than biosimilars filed under the Biologics Price Competition and Innovation Act.

References

  1. U.S. Food and Drug Administration. (2015). FDA approves cobimetinib with vemurafenib for metastatic melanoma with a BRAF V600E or V600K mutation. https://www.fda.gov
  2. U.S. Food and Drug Administration. (2024a). Cotellic (cobimetinib) tablets: Prescribing information. Genentech, Inc. https://www.accessdata.fda.gov
  3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  4. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Patent and exclusivity considerations. https://www.fda.gov
  5. U.S. Food and Drug Administration. (2024c). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.